Voyager Therapeutics appoints new CFO, CSO, and SVP of Corporate Affairs

Voyager Therapeutics, Inc.

Peter Pfreundschuh named CFO effective Sept 19, 2022; base salary $455K, target bonus 40%, 200K option + 125K RSU.
Todd Carter promoted to CSO effective Sept 19, 2022; base salary $410K, target bonus 40%, 165K option.
Trista Morrison appointed SVP of Corporate Affairs and Chief of Staff to CEO effective Sept 19, 2022.
Julie Burek remains VP of Finance; Pfreundschuh assumes principal financial and accounting officer roles.
Equity grants for Pfreundschuh are inducement awards under Nasdaq Listing Rule 5635(c)(4).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Peter P. Pfreundschuh

Chief Financial Officer

VYGR · Voyager Therapeutics, Inc.

Effective: 2022-09-19
Filed: September 7, 2022, 7:59 PM ET

pursuant to which Mr. Pfreundschuh agreed to serve as the Chief Financial Officer of the Company, with the first date of employment to commence on September 19, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter P. Pfreundschuh was appointed as Chief Financial Officer at Voyager Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

pursuant to which Mr. Pfreundschuh agreed to serve as the Chief Financial Officer of the Company, with the first date of employment to commence on September 19, 2022

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-098047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.